Background: Although evidence on the health effects of sedentary behavior (SB) has grown systematically in recent years, few developing countries have reported population levels of SB, especially in South America. Our objective was to describe time spent sitting in a representative sample from Chile categorized by age, gender, educational level, and body mass index (BMI).

Methods: A national health survey was conducted in Chile in a nationally representative sample ( = 5411) in 2009-2010. Sitting time (ST) was measured with the Global Physical Activity Questionnaire Version 2.

Results: Data were from 5031 participants (43.26 ± 0.41 years, mean ± SE; 40.3% male). Overall, there were no gender differences in mean ST (men: 158.10 ± 5.80 min/day, women 143.45 ± 4.77 min/day;  = 0.05). ST was lower in those who lived in rural areas compared with urban areas (99.4 min/day 160.0 min/day;  = 0.001). ST increased significantly with increasing BMI, but only in men ( = 0.009), and was positively related to years of education in both men and women ( < 0.0001).

Conclusion: The findings were different from those reported in other countries and contexts, reinforcing the need for international surveillance and monitoring over time to inform policy makers. Differences in ST across different groups emphasize the need to develop tailored messages and interventions for reducing ST in different population subgroups.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349575PMC
http://dx.doi.org/10.1016/j.jshs.2017.08.002DOI Listing

Publication Analysis

Top Keywords

national health
8
health survey
8
representative sample
8
descriptive epidemiology
4
epidemiology sitting
4
sitting chilean
4
chilean adults
4
adults national
4
survey 2009-2010
4
2009-2010 background
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Karolinska Institute, Stockholm, Södermanland and Uppland, Sweden.

Background: Novel anti-amyloid therapies (AAT) for Alzheimer's Disease (AD) have recently been approved in the United States, Japan and China, and are under regulatory review in Europe. Questions remain regarding the long-term effectiveness and value of these drugs when used in routine clinical practice. Data from follow-up studies will be important to inform their optimal use, including criteria for treatment initiation, monitoring strategies, stopping rules, pricing and reimbursement considerations.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Department of Bioengineering, University of California, Los Angeles, CA, USA, Los Angeles, CA, USA.

Background: The initiation of amyloid plaque deposition signifies a crucial stage in Alzheimer's disease (AD) progression, which often coincides with the disruption of neural circuits and cognitive decline. While the role of excitatory-inhibitory balance is increasingly recognized in AD pathophysiology, targeted therapies to modulate this balance remain underexplored. This study investigates the effect of perampanel, a selective non-competitive AMPA receptor antagonist, in modulating neurophysiological changes in hAPP-J20 transgenic Alzheimer's mice.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Actinogen Medical, Sydney, Australia.

Background: Selecting the optimal dose for clinical development is especially problematic for drugs directed at CNS-specific targets. For drugs with a novel mechanism of action, these problems are often greater. We describe Xanamem's clinical pharmacology, including the approach to dose selection and proof-of-concept studies.

View Article and Find Full Text PDF

Background: Epidemiological studies report an elevated risk of neurodegenerative disorders, particularly Parkinson's disease (PD), in patients with type 2 diabetes mellitus (T2DM) that is mitigated in those prescribed incretin mimetics or dipeptidyl peptidase 4 inhibitors (DPP-4Is). Incretin mimetic repurposing appears promising in human PD and Alzheimer's disease (AD) clinical trials. DPP-4Is are yet to be evaluated in PD or AD human studies.

View Article and Find Full Text PDF

Background: Cilostazol, a selective type-3 phosphodiesterase inhibitor, ameliorates β-amyloid accumulation by facilitating intramural periarterial drainage.

Method: Patients with mild cognitive impairment were registered in the COMCID study, an investigator-initiated, double-blinded, multi-center, phase-II clinical trial. The primary endpoint was the Mini-Mental State Examination score.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!